Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BJDX NASDAQ:FEMY NASDAQ:OSRH NASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$2.96-10.6%$2.80$1.62▼$16.68$2.99M0.82790,732 shs53,110 shsFEMYFemasys$3.87+7.5%$6.83$3.50▼$22.20$11.72M-2.2349,381 shs33,999 shsOSRHOSR$0.33+2.9%$0.50$0.31▼$1.57$11.62M0.614.06 million shs246,539 shsSURGSurgePays$0.38+1.1%$0.53$0.37▼$3.45$9.62M0.31307,163 shs28,107 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+10.70%-25.78%+71.50%+68.88%-47.63%FEMYFemasys-1.91%-10.89%-56.10%-62.69%-81.63%OSRHOSR-4.87%-18.17%-35.23%-31.01%-74.35%SURGSurgePays-3.06%-9.61%-24.83%-48.67%-87.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$2.96-10.6%$2.80$1.62▼$16.68$2.99M0.82790,732 shs53,110 shsFEMYFemasys$3.87+7.5%$6.83$3.50▼$22.20$11.72M-2.2349,381 shs33,999 shsOSRHOSR$0.33+2.9%$0.50$0.31▼$1.57$11.62M0.614.06 million shs246,539 shsSURGSurgePays$0.38+1.1%$0.53$0.37▼$3.45$9.62M0.31307,163 shs28,107 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+10.70%-25.78%+71.50%+68.88%-47.63%FEMYFemasys-1.91%-10.89%-56.10%-62.69%-81.63%OSRHOSR-4.87%-18.17%-35.23%-31.01%-74.35%SURGSurgePays-3.06%-9.61%-24.83%-48.67%-87.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics 1.00SellN/AN/AFEMYFemasys 2.50Moderate Buy$106.672,656.24% UpsideOSRHOSR 1.00SellN/AN/ASURGSurgePays 1.67Reduce$3.50811.46% UpsideCurrent Analyst Ratings BreakdownLatest BJDX, OSRH, FEMY, and SURG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026BJDXBluejay Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/10/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.506/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026SURGSurgePays Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026SURGSurgePays Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/17/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.75 ➝ $5.003/27/2026BJDXBluejay Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay DiagnosticsN/AN/AN/AN/A$8.43 per shareN/AFEMYFemasys$2.29M5.10N/AN/A$2.01 per share1.93OSRHOSR$2.91M3.98N/AN/A$4.95 per share0.07SURGSurgePays$56.96M0.17N/AN/A($0.66) per share-0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$6.85M-$11.63N/AN/AN/AN/A-144.27%-115.00%8/19/2026 (Estimated)FEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)OSRHOSR-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/ASURGSurgePays-$36.07M-$1.94N/A7.68N/A-64.91%-967.32%-310.16%8/12/2026 (Estimated)Latest BJDX, OSRH, FEMY, and SURG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2025SURGSurgePays-$0.19-$0.51-$0.32-$0.51$15.50 million$15.98 million5/13/2026Q1 2026OSRHOSRN/A-$0.09N/A-$0.0880N/A$0.48 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 million5/7/2026Q1 2026BJDXBluejay DiagnosticsN/A-$1.95N/A-$1.95N/AN/A3/31/2026Q4 2025FEMYFemasys-$1.6666-$0.20+$1.4666-$0.01$1.06 million$0.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A2.812.81FEMYFemasys0.533.911.98OSRHOSRN/A0.160.14SURGSurgePaysN/A0.270.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%FEMYFemasys65.27%OSRHOSR55.30%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics6.10%FEMYFemasys7.75%OSRHOSR36.80%SURGSurgePays29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics91.03 million972,000Not OptionableFEMYFemasys303.02 million2.79 millionNot OptionableOSRHOSRN/A35.10 million22.19 millionN/ASURGSurgePays4025.12 million17.81 millionOptionableBJDX, OSRH, FEMY, and SURG HeadlinesRecent News About These CompaniesSurgePays Shareholders Approve Directors and Capital Structure ChangesJune 22, 2026 | tipranks.comSurgePays Secures New Convertible Note Financing DealJune 22, 2026 | tipranks.comSurgePays Q2 EPS Increased by Ascendiant Capital MarketsJune 15, 2026 | americanbankingnews.comInsider Buying: SurgePays (NASDAQ:SURG) Director Acquires 34,716 Shares of StockJune 6, 2026 | insidertrades.comSurgePays Engages BrandRap to Develop AI Decisioning Engine for ProgramBenefits.com to Enhance Subscriber RevenueJune 5, 2026 | quiverquant.comQSurgePays Signs Master Services Agreement with BrandRap to Build Artificial Intelligence (AI) Decisioning Engine to Drive Higher Revenue Per SubscriberJune 5, 2026 | globenewswire.comWhy The Narrative Around SurgePays (SURG) Is Shifting After New Risk And Valuation UpdatesJune 1, 2026 | finance.yahoo.comSurgepays Inc (SURG) Q1 2026 Earnings Call Highlights: Robust Revenue Growth Amid Operational ...May 15, 2026 | finance.yahoo.comSurgePays Delays Quarterly Report Filing BrieflyMay 15, 2026 | tipranks.comSurgePays Reports First Quarter 2026 Revenue of Approximately $16 Million, Up 51% Year-Over-Year Driven by Point of Sale and Prepaid Services Growth of 71%May 15, 2026 | globenewswire.comSurgePays, Inc. Launches 25,000 Activation Pilot to Monetize Subprime Customer Base Through Alpha Cash IntegrationMay 12, 2026 | quiverquant.comQSurgePays Launches Alpha Cash Pilot to Monetize Subprime Consumer Distribution, First in a Planned SeriesMay 12, 2026 | globenewswire.comSurgePays to Host First Quarter 2026 Financial Results Conference Call on May 15thMay 11, 2026 | globenewswire.comHow The SurgePays (SURG) Story Is Shifting As Analysts Rework Valuation AssumptionsMay 3, 2026 | finance.yahoo.comF5 Networks (FFIV) Beats Q2 Earnings and Revenue EstimatesApril 28, 2026 | zacks.comSurgePays Advances AI Decisioning Platform Focused on Increasing Revenue Per User Across the Subprime MarketApril 21, 2026 | globenewswire.comSurgePays, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comSurgePays, Inc. (NASDAQ:SURG) Q4 2025 Earnings Call TranscriptApril 16, 2026 | insidermonkey.comSurgePays (SURG) Q4 2025 Earnings Call TranscriptApril 15, 2026 | fool.comSurgePays, Inc.: SurgePays Reports Full Year 2025 Results and Highlights Scalable Growth Model with Improved Cost Structure Entering 2026April 15, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Mission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026From Crypto to AI: Insiders Are Trading These 3 StocksBy Leo Miller | June 9, 2026CoreWeave Insider Sales Look Big, But Should Investors Worry?By Sam Quirke | June 17, 2026BJDX, OSRH, FEMY, and SURG Company DescriptionsBluejay Diagnostics NASDAQ:BJDX$2.96 -0.35 (-10.57%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Femasys NASDAQ:FEMY$3.87 +0.27 (+7.50%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.OSR NASDAQ:OSRH$0.33 +0.01 (+2.93%) As of 03:52 PM Eastern This is a fair market value price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.SurgePays NASDAQ:SURG$0.38 +0.00 (+1.05%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
